Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

5.415 -0.005 (-0.09%)
Streaming Delayed Price Updated: 10:09 AM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
Breaking Down The Inflation Numbers Draws Attention To Oil Prices
Oil futures (/CL) are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However,... 
Via Benzinga
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. 
Via Talk Markets
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would... 
Via Benzinga
Unusual Options Activity Insight: CureVac
CureVac (NASDAQ:CVAC) shares experienced unusual options ... 
Via Benzinga
Why CureVac's Stock Is Down During Today's Session
CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European... 
Via Benzinga
CureVac Streamlines European Network for mRNA Product Manufacturing
- CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands - Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
- Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis - Further research aimed at optimizing mRNA... 
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?
It isn't likely. 
Via The Motley Fool
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
4 High-Yield Dividend Stocks to Boost Your Dividend Income
Dividends paid by GlaxoSmithKline plc, Vector Group Ltd, Star Group, L.P., and Ennis, Inc translate to high yields at their current price levels. 
Via Talk Markets
Boehringer Ingelheim Scraps Lung Cancer Program With CureVac
CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated... 
Via Benzinga
Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today
Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. 
Via InvestorPlace
Topics Economy
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update - Continuation of corporate transformation into commercial-ready biopharma company-... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
- Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed... 
Via Benzinga
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine
EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (... 
Via Benzinga
Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
CureVac aims to become one of Europe's big suppliers. 
Via The Motley Fool
Unusual Options Activity Insight: CureVac
On Wednesday, shares of CureVac (NASDAQ:CVAC) saw unusual options activity. After the option alert, the stock price moved down to $59.8. Sentiment: BEARISH Option Type: SWEEP... 
Via Benzinga
South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters
South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the... 
Via Benzinga
Here's Why You Should Avoid CureVac Stock Like the Plague
Funds will not be safe if invested in this coronavirus stock. 
Via The Motley Fool
Is CureVac a Bargain Bet on mRNA Vaccine Technology?
CureVac shares have slipped more than 20% on bad news. 
Via The Motley Fool
Topics Cannabis
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Moderna and Pfizer May Benefit From This Rival's Bad News
And it could equal billions of dollars for these vaccine leaders. 
Via The Motley Fool
Topics Cannabis
Can CureVac Recover After Its Vaccine Setback?
Investors' dreams of a third strong mRNA vaccine may be over. 
Via The Motley Fool
Topics Cannabis
58 Biggest Movers From Yesterday
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
Via Benzinga
Topics Initial Public Offering
30 Stocks Moving In Thursday's Mid-Day Session
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 104.6% to $62.00. Pop Culture Group shares jumped 405% on Wednesday after the company priced its IPO at $6 per... 
Via Benzinga
Topics Initial Public Offering
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.